Ataxia Market, by Treatment Type (Pharmacotherapy (Levodopa, Pramipexole, Desvenlafaxine, Venlafaxine, and Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)), Physical Therapy, Speech Therapy, and Others (Adaptive Devices and Occupational Therapy)), by Disease Type (Friedreich's Ataxia, Ataxia-telangiectasia, Spinocerebellar Ataxias, Episodic Ataxia, and Others (Multiple System Atrophy (MSA))), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
Ataxia refers to a group of degenerative neurological diseases that affect coordination and movement center of the brain (cerebellum). People suffering from ataxia have difficulty in swallowing, speech, and maintaining balance or coordination. Ataxia can be classified into three types on the basis of cause: acquired ataxia, genetic ataxia, and idiopathic ataxia. Acquired ataxia is caused by external factors such as vitamin deficiencies, head trauma, microbial infection, brain tumor, and exposure to drugs or alcohol. Genetic ataxia is caused when a damaged gene which leads to ataxia is passed from one generation to the other. Idiopathic ataxia is a condition wherein the cause is unknown. Few of the symptoms associated with ataxia include decreasing coordination, trouble in walking, impaired balance with frequent falls, loss of fine motor skills, muscle tremors, slurred speech, vision problems, and others. Ataxia can develop at any age and is progressive in nature i.e. it worsens with time.
Market Dynamics
The increasing incidence of ataxia, rising research and development activities for the development of novel therapeutics for the treatment of ataxia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global ataxia market over the forecast period.
For instance, according to an article published by the Clinical and Translational Neuroscience journal, in August 2018, it is estimated that the global occurrence rate of ataxia is 26/100,000 in children wherein the occurrence rate for dominant hereditary cerebellar ataxia is 2.7/100,000 and the occurrence rate for recessive hereditary cerebellar ataxia 3.3/100,000, as of 2018.
Key features of the study:
- LI> This report provides in-depth analysis of the global ataxia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ataxia market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Pfizer, Inc., CRISPR Therapeutics, Acorda Therapeutics, Capsida Biotherapeutics Inc., Larimar Therapeutics, Inc., Healx, Intellia Therapeutics, Inc., Editas Medicine, bluebird bio, Inc., Sanofi, Merck & Co., Inc., H. Lundbeck A/S, Cellectis SA, Bio-Techne, GlaxoSmithKline plc, and Allergan
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ataxia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ataxia market
- LI> Global Ataxia Market, By Treatment Type:
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- Global Ataxia Market, By Disease Type:
- Friedreich's Ataxia
- Ataxia-telangiectasia
- Spinocerebellar Ataxias
- Episodic Ataxia
- Others (Multiple System Atrophy (MSA))
- Global Ataxia Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Ataxia Market, By Region:
- North America
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- Latin America
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Treatment Type
- Pharmacotherapy
- Levodopa
- Pramipexole
- Desvenlafaxine
- Venlafaxine
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Physical Therapy
- Speech Therapy
- Others (Adaptive Devices and Occupational Therapy)
- By Disease Type
- Antimetabolite
- Kinase Inhibitors
- Alpha Interferon
- Selective Serotonin Reuptake Inhibitors
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pfizer Inc.*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- CRISPR Therapeutics
- Acorda Therapeutics
- Capsida Biotherapeutics Inc.
- Larimar Therapeutics, Inc.
- Healx
- Intellia Therapeutics, Inc.
- Editas Medicine
- bluebird bio, Inc.
- Sanofi
- Merck & Co., Inc.
- H. Lundbeck A/S
- Cellectis SA
- Bio-Techne
- GlaxoSmithKline plc
- Allergan
- 1. Research Objectives and Assumptions
- o Research Objectives
- o Assumptions
- o Abbreviations
- 2. Market Purview
- o Report Description
- Market Definition and Scope
- o Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Disease Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- o Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- o Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- o Impact Analysis
- o Pipeline Analysis
- o PEST Analysis
- o Regulatory Scenario
- o Market Trends
- o Key Highlights
- o Reimbursement Scenario
- o Mergers & Acquisitions
- 4. Global Ataxia Market – Impact of Coronavirus (Covid-19) Pandemic
- o Economic Impact
- o Impact on Clinical Trials and Drug Development
- o Government Initiatives
- 5. Global Ataxia Market, By Treatment Type, 2017 – 2028, (US$ Mn)
- o Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- o Pharmacotherapy
- Levodopa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Pramipexole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Desvenlafaxine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Venlafaxine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- Others (Acetazolamide, Scopolamine, Buspirone, Tizanidine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Physical Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Speech Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Others (Adaptive Devices and Occupational Therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 6. Global Ataxia Market, By Disease Type, 2017 – 2028, (US$ Mn)
- o Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- o Friedreich's Ataxia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Ataxia-telangiectasia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Spinocerebellar Ataxias
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Episodic Ataxia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Others (Multiple System Atrophy (MSA))
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 7. Global Ataxia Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
- o Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2018 – 2028
- Segment Trends
- o Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- o Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
- 8. Global Ataxia Market, By Region, 2017 – 2028, (US$ Mn)
- o Introduction
- Market Share Analysis, By Region, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, For Regions, 2018–2028
- o North America
- Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- U.S.
- Canada
- o Latin America
- Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- o Europe
- Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- o Asia Pacific
- Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- o Middle East
- Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- o Africa
- Market Size and Forecast, By Treatment Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Disease Type, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 – 2028, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- 9. Competitive Landscape
- o Heat Map Analysis
- o Market Share Analysis
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- CRISPR Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Acorda Therapeutics
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Capsida Biotherapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Larimar Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Healx
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Intellia Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Editas Medicine
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- bluebird bio, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- H. Lundbeck A/S
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Cellectis SA
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bio-Techne
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Allergan
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- o Analyst Views
- 10. Section
- o References
- o Research Methodology
- o About us and Sales Contact
- *Browse 33 market data tables and 25 figures on "Ataxia Market” - Global forecast to 2028
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook